Bionano Genomics (BNGO) Enterprise Value (2017 - 2026)

Bionano Genomics has disclosed Enterprise Value across 10 years of filings, most recently posting -$14.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$14.4 million, up 21.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.4 million (up 21.12% YoY), and the FY2025 annual result was -$19.3 million, down 103.37% from the prior year.
• Enterprise Value came in at -$14.4 million for Q1 2026 at Bionano Genomics, up from -$19.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$5.1 million in Q4 2022 to a low of -$216.4 million in Q1 2022.
• The 5-year median for Enterprise Value is -$19.8 million (2024), against an average of -$61.0 million.
• Across the five-year window, Enterprise Value surged 97.97% in 2022 and slumped 942.33% in 2023, its largest moves.
• Bionano Genomics' Enterprise Value stood at -$5.1 million in 2022, then plunged by 942.33% to -$53.1 million in 2023, then soared by 82.14% to -$9.5 million in 2024, then plunged by 103.37% to -$19.3 million in 2025, then advanced by 25.37% to -$14.4 million in 2026.
• The last three Enterprise Value figures came in at -$14.4 million (Q1 2026), -$19.3 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.